Grifols (NASDAQ:GRFS) Raised to “Hold” at Zacks Research

Grifols (NASDAQ:GRFS) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities analysts also recently weighed in on the stock. Weiss Ratings downgraded shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $10.00.

Grifols Trading Up 1.4%

NASDAQ GRFS opened at $7.31 on Tuesday. The company has a fifty day simple moving average of $7.64 and a two-hundred day simple moving average of $8.36. The stock has a market cap of $4.98 billion, a P/E ratio of 38.47, a P/E/G ratio of 0.28 and a beta of 0.67. Grifols has a 12-month low of $6.96 and a 12-month high of $11.14. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently added to or reduced their stakes in GRFS. Bank of Montreal Can increased its holdings in shares of Grifols by 3,205.1% in the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock valued at $30,017,000 after purchasing an additional 2,922,540 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after acquiring an additional 2,221,633 shares during the last quarter. Norges Bank acquired a new stake in shares of Grifols in the 4th quarter worth $18,139,000. Brandes Investment Partners LP raised its holdings in shares of Grifols by 6.3% during the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after acquiring an additional 1,838,727 shares during the period. Finally, Barclays PLC boosted its position in shares of Grifols by 132.6% during the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock valued at $22,764,000 after acquiring an additional 1,387,783 shares during the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.